Featured on In Vivo: “Rgenix: A Cancer Start-Up’s Resolve To Crack The Mystery Of Metastasis”
Rgenix, a New York-based start-up co-founded by three prominent physician researchers, is taking aim at what it contends is the future of cancer treatment: finding drugs that shut off the biological chain reaction called tumor metastasis – the colonization of
Rgenix Names Industry Veteran to Chief Medical Officer Role
Robert Wasserman, MD, joins Rgenix with more than 20 years of oncology clinical development experience and prior senior roles in the biopharma industry. Wasserman will oversee new Phase 1b/2 trial of lead compound RGX-104 in lung cancer patients; and RGX-202
Rgenix Presents Pre-Clinical Data on RGX-019 at the 2019 AACR Annual Meeting
Pre-clinical data demonstrates first-in-class MERTK selective inhibitor with novel mechanism of action Rgenix has initiated IND-enabling studies of RGX-019 FOR IMMEDIATE RELEASE New York, NY – April 3, 2019 – Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody
Rgenix To Present Abstract on RGX-019 at the 2019 AACR Annual Meeting
New York, NY – April 1, 2019- Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that Isabel Kurth, Ph.D., Vice President of Research at Rgenix, will present an abstract about Rgenix’s
Translational and Clinical Development Strategies for IO Agents Targeting the Innate Immune System
Immuno-Oncology 360° | Crown Plaza Time Square, New York City | February 6, 2019 Masoud Tavazoie, Rgenix CEO and Co-Founder speaks at Immuno-Oncology 360° In its 5th year, the IO360 conference brings together diverse stakeholders of drug development in immuno-oncology (IO). The